49 results on '"Fagerli UM"'
Search Results
2. High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T-cell lymphoma - final analysis of a large prospective multicenter study (NLG-T-01)
- Author
-
D'Amore, Francesco Annibale, Relander, T, Lauritzsen, GF, Jantunen, E, Hagberg, H, Anderson, H, Holte, H, Østerborg, A, Merup, M, Brown, Peter De Nully, Østenstad, B, Kuittinen, O, Erlanson, M, Fagerli, UM, Gadeberg, O, Sundström, C, Delabie, J, Ralfkiaer, E, Vornanen, M, and Toldbod, H
- Published
- 2012
3. First interim safety analysis of a phase III randomized trial in a newly diagnosed systemic peripheral T-cell lymphoma trated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant
- Author
-
D'Amore, Francesco Annibale, Gomes da Silva, M, Leppa, S, Relander, T, Pezzutto, A, Lauritzsen, GF, Weidmann, E, Van Gelder, M, Merup, M, Hagberg, H, Fagerli, UM, Brown, Peter De Nully, Boye Hansen, P, Mariz, JM, Jankovska, M, Walewski, J, Doorduijn, J, van Hoof, A, Christiansen, Ilse, Jyrkkiö, S, Kluin-Nelemans, JC, van Marwijk Kooy, M, Fijnheer, R, Stevens, W, Zijlstra, J, Böhmer, L, Lugtenburg, PJ, Grube, M, Prochazka, V, Salek, D, Greil, R, Trümper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M, Jantunen, E, Hopfinger, G, Van den Neste, E, and Toldbod, H
- Published
- 2011
4. CHOEP-14 and autologous stem cell tranplantation (ASCT) in angioimmunoblastic T-cell lymphoma: a prospective study by the Nordic Lymphoma Group (NLG-T-01)
- Author
-
Lauritzsen, GF, Relander, T, Jantunen, E, Hagberg, H, Anderson, H, Merup, M, Brown, P, Østenstad, B, Kuittinen, O, Erlanson, M, Fagerli, UM, Delabie, J, Sundström, C, Ralfkiaer, E, Vornanen, M, and D'Amore, Francesco Annibale
- Published
- 2011
5. Distressed personality is associated with late adverse effects in long-term survivors of Hodgkin lymphoma.
- Author
-
Dahl AA, Smeland KB, Eikeland S, Fagerli UM, Bersvendsen HS, Fosså A, and Kiserud CE
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Cross-Sectional Studies, Adolescent, Young Adult, Child, Surveys and Questionnaires, Fatigue epidemiology, Fatigue etiology, Fatigue psychology, Stress Disorders, Post-Traumatic epidemiology, Stress Disorders, Post-Traumatic etiology, Stress Disorders, Post-Traumatic psychology, Sleep Wake Disorders etiology, Sleep Wake Disorders epidemiology, Sleep Wake Disorders psychology, Long Term Adverse Effects psychology, Long Term Adverse Effects epidemiology, Long Term Adverse Effects etiology, Hodgkin Disease psychology, Cancer Survivors psychology, Cancer Survivors statistics & numerical data, Personality
- Abstract
Background and Purpose: There are few studies of personality traits in long-term Hodgkin lymphoma survivors (HLSs) treated according to contemporary stage-and risk-adapted approaches. The Distressed Personality (DP) Scale covers negative affectivity and social inhibition. We examined differences in self-reported late adverse effects (LAEs) between HLSs with and without DP and other explanatory variables., Material and Methods: This cross-sectional questionnaire-based study included a population-based cohort of HLSs treated from 1997 to 2006, aged 8-49 years at diagnosis, and alive in 2016. Among 518 eligible HLSs, 303 responded (58%), and 294 completed the DP scale. DP was defined by scores above cut-off on both the negative affectivity and social inhibition subscales. LAEs studied were major depression, posttraumatic stress disorder, sleep problems, obesity, neuropathy, fatigue, memory problems, and general health. DP and 10 other explanatory variables were tested against LAEs as dependent variables in multivariable regression analyses., Results: The mean age at survey was 45.9 years (standard deviation [SD] 4.6), mean follow-up time 16.7 years (SD 3.0), and 48% were females. Eighty-two HLSs had DP (28%, 95% confidence interval 23% - 33%). All LAEs except obesity were significantly more common/had higher mean score in HLSs with DP. In multivariable analyses, presence of DP was significantly associated with all LAEs except obesity., Interpretation: The presence of DP is common among HLSs. The presence of DP was associated with most self-report LAEs examined. Including assessment of personality traits in the survivorship care plans of HLSs should be considered. Prospective studies assessing the influence of pretreatment DP on LAEs are warranted.
- Published
- 2024
- Full Text
- View/download PDF
6. Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.
- Author
-
Pulczynski EJ, Simonsen MR, Kuittinen O, Fagerli UM, Erlanson M, Fluge Ø, Leppä S, Østenstad B, Fosså A, Eriksson M, El-Galaly T, Kuitunen H, Papworth K, Ljungqvist M, Pedersen MB, and Pollari M
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Antineoplastic Agents, Alkylating therapeutic use, Antineoplastic Agents, Alkylating adverse effects, Cancer Survivors, Dacarbazine therapeutic use, Dacarbazine administration & dosage, Follow-Up Studies, Lymphoma drug therapy, Lymphoma mortality, Maintenance Chemotherapy, Treatment Outcome, Central Nervous System Neoplasms drug therapy, Central Nervous System Neoplasms mortality, Temozolomide therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
7. Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study.
- Author
-
Lia K, Jørgensen RRK, L Wold B, Fluge Ø, Fagerli UM, Bersvendsen H, Bø IB, Bhargava S, and Fosså A
- Subjects
- Humans, Norway epidemiology, Aged, Male, Female, Case-Control Studies, Aged, 80 and over, Middle Aged, Population Surveillance, Survival Rate, Hodgkin Disease mortality, Hodgkin Disease therapy, Registries, Cause of Death
- Abstract
Elderly Hodgkin lymphoma (HL) patients are poorly characterized and under-represented in studies. In this national population- based study, we investigated cause-specific survival using competing-risk analysis in elderly HL patients compared to the normal population. Patients ≥60 years of age diagnosed between 2000-2015 were identified by the Cancer Registry of Norway, and records were reviewed in detail and compared to data from the Norwegian Cause of Death Registry for patients and cancer-free controls. Of 492 patients, 81 (17%) were ineligible for treatment directed specifically towards HL, mostly because of an underlying other lymphoma entity, whereas 74 (15%) and 337 (69%) were treated with palliative or curative intent, respectively. Median overall survival in patients ineligible for assessment of HL-directed therapies was 0.5 years (95% Confidence Interval [CI]: 0.4-0.6), and for palliatively and curatively treated patients 0.8 (0.4-1.2) and 9.1 (7.5-10.7) years, respectively. After correction of discrepancies in registry data, with 359 deaths, 108 (30%) died of HL, the most common cause of death. In curatively treated patients, treatment-related mortality was 6.5% and the risk difference of dying from HL compared to controls was 28% (95% CI: 23-33%) after ten years. These numbers indicate disease control in a majority of elderly patients eligible for curative treatment, compared to risk differences for death from HL of 59% (48-71%) and 42% (31-53%) after ten years in the palliative and ineligible groups, respectively. There was an increased risk of dying from hematologic malignancies other than HL in all groups, but not from other competing causes of death, showing no excess mortality from long-term treatment complications.
- Published
- 2024
- Full Text
- View/download PDF
8. 18 F-FACBC and 18 F-FDG PET/MRI in the evaluation of 3 patients with primary central nervous system lymphoma: a pilot study.
- Author
-
Husby T, Johannessen K, Berntsen EM, Johansen H, Giskeødegård GF, Karlberg A, Fagerli UM, and Eikenes L
- Abstract
Background: This PET/MRI study compared contrast-enhanced MRI,
18 F-FACBC-, and18 F-FDG-PET in the detection of primary central nervous system lymphomas (PCNSL) in patients before and after high-dose methotrexate chemotherapy. Three immunocompetent PCNSL patients with diffuse large B-cell lymphoma received dynamic18 F-FACBC- and18 F-FDG-PET/MRI at baseline and response assessment. Lesion detection was defined by clinical evaluation of contrast enhanced T1 MRI (ce-MRI) and visual PET tracer uptake. SUVs and tumor-to-background ratios (TBRs) (for18 F-FACBC and18 F-FDG) and time-activity curves (for18 F-FACBC) were assessed., Results: At baseline, seven ce-MRI detected lesions were also detected with18 F-FACBC with high SUVs and TBRs (SUVmax :mean, 4.73, TBRmax : mean, 9.32, SUVpeak : mean, 3.21, TBRpeak :mean: 6.30). High TBR values of18 F-FACBC detected lesions were attributed to low SUVbackground . Baseline18 F-FDG detected six lesions with high SUVs (SUVmax : mean, 13.88). In response scans, two lesions were detected with ce-MRI, while only one was detected with18 F-FACBC. The lesion not detected with18 F-FACBC was a small atypical MRI detected lesion, which may indicate no residual disease, as this patient was still in complete remission 12 months after initial diagnosis. No lesions were detected with18 F-FDG in the response scans., Conclusions:18 F-FACBC provided high tumor contrast, outperforming18 F-FDG in lesion detection at both baseline and in response assessment.18 F-FACBC may be a useful supplement to ce-MRI in PCNSL detection and response assessment, but further studies are required to validate these findings. Trial registration ClinicalTrials.gov. Registered 15th of June 2017 (Identifier: NCT03188354, https://clinicaltrials.gov/study/NCT03188354 )., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
9. Work ability and work status changes in long-term Hodgkin lymphoma survivors with focus on late adverse effects.
- Author
-
Dahl AA, Smeland KB, Eikeland S, Fagerli UM, Bersvendsen HS, Fosså A, and Kiserud CE
- Abstract
Purpose: We studied work-related issues in long-term survivors of Hodgkin lymphoma [HLSs] who had undergone treatment according to contemporary stage risk-adapted approaches. At survey, work changes and problems since diagnosis, comparisons of HLSs with low/moderate versus high work ability, associations between work issues, and late adverse effects [LAEs] were examined., Methods: This cross-sectional questionnaire-based study included HLSs treated from 1997 to 2006 and alive at the end of 2016. They completed a mailed questionnaire including work and health-related issues., Results: Among 518 invited HLSs, 297 (58%) completed the work-related issues, and 48% of them were females. Mean age at survey was 45.9 years, and mean time was 16.7 years since diagnosis. At follow-up, 71% of the HLSs held paid work and 19% were on disability pension. Only 3% of HLSs did not hold paid work at any time after diagnosis. In total, 43% HLSs had low/moderate and 57% high work ability at follow-up. Low/moderate work ability was significantly associated with older age, female sex, more LAEs, disability pension, lower household income, distressed personality, obesity, fatigue, and mental disorders. More LAEs were significantly associated with more work problems., Conclusions: Many HLSs manage to stay in the work force. Several health problems and LAEs amenable for interventions are significantly associated with low/moderate work ability and emphasize the importance of focus on these issues in long-term follow-up., Implications for Cancer Survivors: HLSs in paid work at diagnosis can be optimistic as to their future participation in work life. Screening and treatment for health problems such as LAEs may improve work ability., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
10. Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment.
- Author
-
Eikeland SA, Smeland KB, Simensen VC, Fagerli UM, Bersvendsen HS, Kiserud CE, and Fosså A
- Subjects
- Humans, Female, Middle Aged, Male, Cross-Sectional Studies, Survivors, Surveys and Questionnaires, Quality of Life, Hodgkin Disease radiotherapy, Hodgkin Disease diagnosis, Fatigue Syndrome, Chronic epidemiology
- Abstract
Background: Chronic fatigue (CF), substantial fatigue for ≥ six months, can manifest as a late effect (LE) after cancer treatment, and may affect several aspects of life. In a Norwegian cohort of Hodgkin's lymphoma survivors (HLS), more than a decade after contemporary risk-adapted treatment regimens with limited use of radiotherapy (RT), we assessed: (1) Prevalence of, (2) factors associated with (3) and implications of CF on socioeconomic status (SES) and work ability (WA)., Material and Methods: HLS treated between 1997-2006, aged 8-49 years at diagnosis, were invited to participate in a population-based cross-sectional study on late effects in 2018-2019. In a mailed questionnaire, HLS responded to a fatigue questionnaire (FQ), work ability score (WAS) and short-form health survey (SF-36). Disease- and treatment data were extracted from hospital records. Factors associated with CF were identified by uni- and multivariate analysis. To study the implications of CF on SES and WA, a multinomial regression analysis was performed., Results: Invitations were extended to 518 HLS and 298 (58%) responded to FQ, of whom 42% had CF with mean (standard deviation [SD]) physical- and mental fatigue scores of 10.2 (4.3) and 5.5 (2.1) respectively. Median age at survey was 45 years, 47% were females. In multivariate analysis female sex ( p = 0.03), lower education ( p = 0.03), body mass index ≥30 kg/m
2 ( p = 0.04), and an increasing number of comorbidities ( p = 0.01) were associated with CF. No association with disease stage, chemotherapy or RT was found. CF was associated with poorer WAS scores at survey ( p < 0.001), unemployment ( p = 0.03), and receiving disability pension ( p = 0.003)., Conclusion: After risk-adapted treatment, CF is still a frequent LE among long-term HLS, without apparent association with disease or treatment-related parameters. CF is associated with reduced WA and SES. As no apparent risk reduction is seen with contemporary treatment, further studies should emphasize etiological factors of CF and treatment to alleviate this common LE.- Published
- 2023
- Full Text
- View/download PDF
11. Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.
- Author
-
Husby T, Johansen H, Bogsrud TV, Hustad KV, Evensen BV, Boellaard R, Giskeødegård GF, Fagerli UM, and Eikenes L
- Subjects
- Humans, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Tumor Burden, Prognosis, Prospective Studies, Retrospective Studies, Positron-Emission Tomography methods, Magnetic Resonance Imaging methods, Radiopharmaceuticals, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse pathology
- Abstract
Purpose: The aim of this prospective study was to investigate the prognostic value of metabolic tumor volume (MTV) and apparent diffusion coefficient (ADC) from baseline FDG PET/MRI compared to established clinical risk factors in terms of progression free survival (PFS) at 2 years in a cohort of diffuse large B-cell Lymphoma (DLBCL) and high-grade-B-cell lymphoma (HGBCL)., Methods: Thirty-three patients and their baseline PET/MRI examinations were included. Images were read by two pairs of nuclear medicine physicians and radiologists for defining lymphoma lesions. MTV was computed on PET, and up to six lymphoma target lesions with restricted diffusion was defined for each PET/MRI examination. Minimum ADC (ADC
min ) and the corresponding mean ADC (ADCmean ) from the target lesion with the lowest ADCmin were included in the analyses. For the combined PET/MRI parameters, the ratio between MTV and the target lesion with the lowest ADCmin (MTV/ADCmin) and the corresponding ADCmean (MTV/ADCmean ) was calculated for each patient. Clinical, histological, and PET/MRI parameters were compared between the treatment failure and treatment response group, while survival analyses for each variable was performed by using univariate Cox regression. In case of significant variables in the Cox regression analyses, Kaplan-Meier survival analyses with log-rank test was used to study the effect of the variables on PFS., Results: ECOC PS scale ≥2 (p = 0.05) and ADCmean (p = 0.05) were significantly different between the treatment failure group (n = 6) and those with treatment response (n = 27). Survival analyses showed that ADCmean was associated with PFS (p = 0.02, [HR 2.3 for 1 SD increase]), while combining MTV and ADC did not predict outcome. In addition, ECOG PS ≥2 (p = 0.01, [HR 13.3]) and histology of HGBCL (p = 0.02 [HR 7.6]) was significantly associated with PFS., Conclusions: ADCmean derived from baseline MRI could be a prognostic imaging biomarker for DLBCL and HGBCL. Baseline staging with PET/MRI could therefore give supplementary prognostic information compared to today's standard PET/CT., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
12. Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life.
- Author
-
Smeland K, Holte H, Fagerli UM, Bersvendsen H, Hjermstad MJ, Loge JH, Murbrach K, Linnsund MD, Fluge O, Stenehjem JS, Lund MB, Kvaloy S, and Kiserud CE
- Subjects
- Adult, Female, Humans, Quality of Life, Transplantation, Autologous, Survivors, Lymphoma therapy, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Lymphoma survivors after high-dose therapy with autologous stem-cell transplant (HDT-ASCT) are at risk of several late effects, which might impair their health-related quality of life (HRQoL). We assessed the total late effect burden in this population, and how it affects HRQoL. All lymphoma survivors treated with HDT-ASCT as adults in Norway between 1987 and 2008 were identified, and 271 (68%) attended both a comprehensive clinical assessment and completed a questionnaire. Severity of 45 conditions in 12 organ-system categories were graded as mild, moderate, severe or life-threatening, according to a modified version of CTCAEv4.03. At a median of 8 years after HDT-ASCT, 98% of survivors had at least one moderate or more severe late effect and 56% had severe or life-threatening late effects. Fourteen percent had low, 39% medium and 47% high late effect burden, defined as having moderate or more severe late effects in 0-1, 2-3 and >3 organsystems, respectively. Female sex, increasing age, B-symptoms at diagnosis and >1 treatment line prior to HDT-ASCT were independently associated with having high late effect burden. The survivors had significantly poorer physical and mental HRQoL assessed by the Short Form-36 compared to age- and sex-matched controls. The prevalence of poor physical and mental HRQoL increased with higher late effect burden (both P<0.001), and the low burden group had better physical HRQoL than controls (P<0.001). In conclusion, lymphoma survivors after HDT-ASCT have impaired HRQoL, seemingly driven by a high late effect burden. This highlights the importance of prevention, regular assessments for early detection and treatment of late effects and modifiable risk factors.
- Published
- 2022
- Full Text
- View/download PDF
13. A comparison of FDG PET/MR and PET/CT for staging, response assessment, and prognostic imaging biomarkers in lymphoma.
- Author
-
Husby T, Johansen H, Bogsrud T, Hustad KV, Evensen BV, Boellard R, Giskeødegård GF, Fagerli UM, and Eikenes L
- Subjects
- Fluorodeoxyglucose F18, Humans, Neoplasm Staging, Prognosis, Radiopharmaceuticals, Reproducibility of Results, Lymphoma, Large B-Cell, Diffuse diagnostic imaging, Positron Emission Tomography Computed Tomography
- Abstract
The aim of the current study was to investigate the diagnostic performance of FDG PET/MR compared to PET/CT in a patient cohort including Hodgkins lymphoma, diffuse large B-cell lymphoma, and high-grade B-cell lymphoma at baseline and response assessment. Sixty-one patients were examined with FDG PET/CT directly followed by PET/MR. Images were read by two pairs of nuclear medicine physicians and radiologists. Concordance for lymphoma involvement between PET/MR and the reference standard PET/CT was assessed at baseline and response assessment. Correlation of prognostic biomarkers Deauville score, criteria of response, SUVmax, SUVpeak, and MTV was performed between PET/MR and PET/CT. Baseline FDG PET/MR showed a sensitivity of 92.5% and a specificity 97.9% compared to the reference standard PET/CT (κ 0.91) for nodal sites. For extranodal sites, a sensitivity of 80.4% and a specificity of 99.5% were found (κ 0.84). Concordance in Ann Arbor was found in 57 of 61 patients (κ 0.92). Discrepancies were due to misclassification of region and not lesion detection. In response assessment, a sensitivity of 100% and a specificity 99.9% for all sites combined were found (κ 0.92). There was a perfect agreement on Deauville scores 4 and 5 and criteria of response between the two modalities. Intraclass correlation coefficient (ICC) for SUVmax, SUVpeak, and MTV values showed excellent reliability (ICC > 0.9). FDG PET/MR is a reliable alternative to PET/CT in this patient population, both in terms of lesion detection at baseline staging and response assessment, and for quantitative prognostic imaging biomarkers., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
14. Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma; symptom burden and quality of life.
- Author
-
Eikeland SA, Smeland KB, Mols F, Fagerli UM, Bersvendsen HS, Kiserud CE, and Fosså A
- Subjects
- Female, Humans, Quality of Life, Surveys and Questionnaires, Antineoplastic Agents adverse effects, Hodgkin Disease drug therapy, Hodgkin Disease epidemiology, Peripheral Nervous System Diseases chemically induced, Peripheral Nervous System Diseases epidemiology
- Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin's lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and determine associated factors, including impact on health-related quality of life (HRQoL)., Material and Methods: A questionnaire, including EORTC QLQ-CIPN-20 for CIPN related symptoms and SF-36 for HRQoL, was completed by 303 HL survivors at a median of 16 years after diagnosis. CIPN results were compared to a normative population ( n = 606). CIPN associated factors were identified by linear regression analysis., Results: Total CIPN score and subscores were significantly higher in HL survivors compared to controls. In multivariate analysis of HL survivors, a number of comorbidities ( p < 0.001) and female gender ( p = 0.05) were significantly associated with more CIPN. No association with disease or treatment factors was found. In a multivariate analysis including survivors and controls, the number of comorbidities ( p < 0.001) and caseness ( p < 0.001) were significantly associated with more CIPN. In HL survivors higher CIPN score was associated with reduced HRQoL ( p < 0.001)., Conclusion: HL survivors more than a decade after treatment report higher neuropathy-related symptom burden than controls, with a negative impact on HRQoL. Symptoms may be related to factors other than neurotoxic chemotherapy.
- Published
- 2021
- Full Text
- View/download PDF
15. Using blood calprotectin as a measure of blood neutrophils.
- Author
-
Åsberg A, Løfblad L, Felic A, Aune MW, Hov GG, and Fagerli UM
- Subjects
- Adult, Aged, Female, Humans, Leukocyte Count, Male, Middle Aged, Neutropenia blood, Neutropenia chemically induced, Regression Analysis, Leukocyte L1 Antigen Complex blood, Neutrophils
- Abstract
Presently, bed-side or at home quantification of neutrophils in blood (b-neutrophils) is not practical, because cytometric methods are too expensive and technically demanding. We have explored whether calprotectin concentration in whole blood (b-calprotectin) might be a valid measure of b-neutrophils because this principle might be used in a simple and robust immunoassay device. We obtained heparin blood samples from 77 patients with possible neutropenia, most of them cancer patients treated with cytostatic drugs, and compared b-calprotectin with their b-neutrophils in a simultaneously taken EDTA-blood sample. The Spearman rank correlation coefficient between b-calprotectin and b-neutrophils was 0.986 ( p < .0001). In a regression model of b-neutrophils as a function of age, gender, type of hematology instrument, total leukocyte count minus neutrophils, b-calprotectin, and plasma calprotectin (p-calprotectin), only b-calprotectin was a statistically significant predictor. B-neutrophils below 1 × 10
9 /L was unlikely if b-calprotectin was above 50 mg/L. In conclusion, b-calprotectin, without adjusting for p-calprotectin, correlates closely with b-neutrophils and could be used to detect b-neutrophils below 1 × 109 /L.- Published
- 2021
- Full Text
- View/download PDF
16. Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress.
- Author
-
Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Wilsgaard T, Smeland KB, and Kiserud CE
- Subjects
- Aged, Female, Humans, Norway epidemiology, Survivors, Transplantation, Autologous, Fatigue Syndrome, Chronic, Hematopoietic Stem Cell Transplantation adverse effects, Lymphoma therapy
- Abstract
Sexual function in female lymphoma survivors after high-dose therapy with autologous stem-cell transplantation (auto-SCT) is largely unstudied. Female lymphoma survivors treated with auto-SCT in Norway 1987-2008 were eligible participants (n = 157). A multi-item questionnaire including a complete Sexual Activity Questionnaire was returned by 70% (n = 110) of the women. A comparison to age-matched normative controls was performed. Sexual inactivity was equal among survivors and controls. The survivors reported personal issues more frequent as reason for inactivity compared with controls (44% vs. 28%, p = 0.04). The sexually active survivors reported more sexual discomfort, greater reduction in frequency of sexual activity, and more sex-related tiredness compared with controls (p value and effect size [95% confidence interval]; p ≤ 0.001, 0.70 [0.44, 0.97], p = 0.03, -0.29 [-0.55, -0.03] and p ≤ 0.001, 0.64 [0.37, 0.90], respectively). Sexual activity was related to older age (odds ratio (OR) 0.58 [0.43, 0.82] per 10 years), being in a relationship (OR 28.6 [6.9, 118.9]) and hormonal replacement therapy (OR 6.0 [1.49, 24.2]). Tiredness in relation to sexual activity was associated with younger age, chronic fatigue and mental distress. Sexual inactivity due to personal issues was more frequent and among those sexually active, a higher rate of sexual dysfunction exists among auto-SCT survivors compared with controls. Hence, sexual function should be addressed at regular timepoints during the cancer trajectory.
- Published
- 2021
- Full Text
- View/download PDF
17. Post-treatment work patterns amongst survivors of lymphoma treated with high-dose chemotherapy with autologous stem-cell transplantation.
- Author
-
Hernæs KH, Smeland KB, Fagerli UM, and Kiserud CE
- Subjects
- Adult, Aged, Combined Modality Therapy, Cross-Sectional Studies, Female, Follow-Up Studies, Humans, Lymphoma therapy, Male, Middle Aged, Prognosis, Retrospective Studies, Surveys and Questionnaires, Transplantation, Autologous, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cancer Survivors psychology, Employment statistics & numerical data, Hematopoietic Stem Cell Transplantation methods, Lymphoma psychology, Quality of Life
- Abstract
Background: This study describes post-treatment work patterns in lymphoma survivors treated with high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). It aims to identify determinants for labour force participation and exclusion after HDT-ASCT., Methods: All survivors treated with HDT-ASCT for lymphoma in Norway between 1995 and 2008, aged ≥18 years at HDT-ASCT and alive at survey in 2012-2013 were eligible. We divide survivors by current employment status (full-time, part-time and unemployed). Main outcomes are current employment status, work hours and work ability. Withdrawals are patients employed when diagnosed but not before HDT-ASCT., Results: Of the 274 who completed the survey, 82% (N = 225) were included in the final analyses. Mean age at survey was 52 years, 39% were female, 85% were employed when diagnosed, 77% before HDT-ASCT and 69% at survey. Employment before HDT-ASCT corresponds with a higher probability of employment at survey for a given symptom burden. In the most extensive statistical model, it increases with 37.3 percentage points. Work hours amongst withdrawals plummet after HDT-ASCT while work ability shows a rebound effect. The potential economic gain from their re-enter into the work force equals 70% of the average annual wage in Norway in 2012., Conclusions: For a given symptom burden, staying employed throughout diagnosis and treatment is associated with a higher probability of future employment. These results favour policies for labour force inclusion past diagnosis and treatment increasing cancer survivors' probability of future employment. However, we need more research on withdrawal mechanisms, and on policy measures that promote inclusion.
- Published
- 2021
- Full Text
- View/download PDF
18. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3.
- Author
-
Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, Räty R, Gjerdrum LMR, Sonnevi K, Josefsson P, Nilsson-Ehle H, Bentzen HHN, Fagerli UM, Kuittinen O, Haaber J, Niemann CU, Pedersen LB, Larsen MT, Geisler CH, Hutchings M, Jerkeman M, and Grønbæk K
- Abstract
Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The prognosis after relapse is generally poor, and no standard of care exists. We investigated the postrelapse outcomes of 149 patients who were initially treated in the Nordic Lymphoma Group trials, MCL2 or MCL3, both representing intensive cytarabine-containing frontline regimens including autologous stem cell transplant. Patients with progression of disease before 24 months (POD24, n = 51, 34%) displayed a median overall survival of 6.6 months compared with 46 months for patients with later POD (n = 98, 66%; P < 0.001). MCL international prognostic index, cell proliferation marker, blastoid morphology, and TP53 mutations showed independent prognostic value irrespective of POD24, and in a combined, exploratory risk score, patients with 0, 1, 2-3, or 4-5 high-risk markers, respectively, displayed a 5-year overall survival of 62%, 39%, 31%, and 0%. By a comparison of median progression-free survival of the different salvage therapies in the relapse setting, bendamustine-rituximab was superior to all other combination chemotherapy regimens; however, it was also associated with longer responses to last line of therapy. Collectively, we confirm the prognostic impact of POD24 and highlight the relevance of other biomarkers, and we emphasize the importance of novel therapies for patients with high-risk features at first POD., Competing Interests: IG has received IG Honoraria from Janssen. CUN has received consultancy fees and/or travel grants from Janssen, Abbvie, Novartis, Roche, Sunesis, Gilead, AstraZeneca, and CSL Behring, and research funding from Novo Nordisk Foundation, grant NNF16OC0019302, Abbvie, AstraZeneca and Janssen, outside this project. All the other authors have no conflicts of interest to disclose., (Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)
- Published
- 2020
- Full Text
- View/download PDF
19. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
- Author
-
Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, and Holte H
- Subjects
- Antibodies, Monoclonal therapeutic use, Humans, Quality of Life, Rituximab, Immunoconjugates, Lymphoma, Non-Hodgkin drug therapy, Lymphoma, Non-Hodgkin radiotherapy
- Abstract
For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. 177Lu-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1/2a study in 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of 177Lu-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the "cold" anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with ≥2 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL ≥2 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). 177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. This trial was registered at www.clinicaltrials.gov as #NCT01796171., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
20. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.
- Author
-
Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, Fagerli UM, Larsen TS, Mannisto S, Munksgaard L, Maisenhölder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Liestøl K, Ralfkiaer E, Spetalen S, Beiske K, Karjalainen-Lindsberg ML, and Holte H
- Subjects
- Adolescent, Adult, Humans, Middle Aged, Neoplasm Recurrence, Local drug therapy, Rituximab therapeutic use, Vincristine therapeutic use, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression is relatively high. We conducted a phase 2 trial in 139 patients aged 18 to 64 years who had primary DLBCL with an age-adjusted International Prognostic Index (aaIPI) score of 2 to 3 or site-specific risk factors for CNS recurrence. The goal was to assess whether a dose-dense immunochemotherapy with early systemic CNS prophylaxis improves the outcome and reduces the incidence of CNS events. Treatment consisted of 2 courses of high-dose methotrexate in combination with biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), followed by 4 courses of R-CHOP-14 with etoposide (R-CHOEP) and 1 course of high-dose cytarabine with R. In addition, liposomal cytarabine was administered intrathecally at courses 1, 3, and 5. Coprimary endpoints were failure-free survival and CNS progression rates. Thirty-six (26%) patients experienced treatment failure. Progression occurred in 23 (16%) patients, including three (2.2%) CNS events. At 5 years of median follow-up, failure-free survival, overall survival, and CNS progression rates were 74%, 83%, and 2.3%, respectively. Treatment reduced the risk of progression compared with our previous trial, in which systemic CNS prophylaxis was given after 6 courses of biweekly R-CHOEP (hazard ratio, 0.49; 95% CI, 0.31-0.77; P = .002) and overcame the adverse impact of an aaIPI score of 3 on survival. In addition, outcome of the patients with BCL2/MYC double-hit lymphomas was comparable to the patients without the rearrangements. The results are encouraging, with a low toxic death rate, low number of CNS events, and favorable survival rates. This trial was registered at www.clinicaltrials.gov as #NCT01325194., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
21. Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation.
- Author
-
Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Seland M, Wilsgaard T, Smeland KB, and Kiserud CE
- Subjects
- Cross-Sectional Studies, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Survivors, Hematopoietic Stem Cell Transplantation adverse effects, Lymphoma therapy
- Abstract
Reduced sexual function may have negative implications on health related quality of life among lymphoma survivors. A national cross-sectional study among long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplantation auto-SCT treated during 1987-2008 was conducted in 2012-2014. The current study explored sexual functioning among these survivors. Sixty-six percent (n = 159) of eligible men with complete questionnaire data were included, median age was 55 years. The Brief Sexual Function Inventory (BSFI) was used to assess sexual function and sexual satisfaction, compared with age-matched controls. In addition, sexual problems were defined based on predetermined cutoff values for BSFI domain scores. Sexual drive and erections firm enough to have sexual intercourse were reported to be present only a few days or less last month among 30% and 41% of survivors, respectively. Sexual satisfaction was reported by 39% of survivors. The survivors had significantly lower scores on all BSFI domains and an increased risk of problems with sexual drive and erection compared with controls. In multivariable models, cardiovascular disease was significantly associated with worse erectile function, while age > 55 years, chronic fatigue, and physical inactivity were significantly associated with lower sexual functioning overall. Chronic fatigue and anxiety were related to lower sexual satisfaction.
- Published
- 2020
- Full Text
- View/download PDF
22. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.
- Author
-
Fosså A, Smeland K, Fagerli UM, Galleberg RB, Bersvendsen HS, and Holte H
- Subjects
- Adult, Allografts, Female, Hodgkin Disease mortality, Hodgkin Disease pathology, Humans, Male, Middle Aged, Norway, Recurrence, Stem Cell Transplantation, Survival Analysis, Transplantation, Autologous, Treatment Outcome, Antineoplastic Agents, Immunological therapeutic use, Brentuximab Vedotin therapeutic use, Hodgkin Disease therapy
- Published
- 2020
- Full Text
- View/download PDF
23. Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma.
- Author
-
Simensen VC, Smeland KB, Kiserud CE, Dahl AA, Bersvendsen HS, Fluge Ø, Fagerli UM, and Fosså A
- Subjects
- Adolescent, Adult, Age Factors, Aged, Cancer Survivors statistics & numerical data, Child, Female, Health Behavior, Hematopoietic Stem Cell Transplantation methods, Humans, Lymphoma diagnosis, Lymphoma radiotherapy, Lymphoma surgery, Male, Mental Recall, Middle Aged, Norway, Patient Education as Topic, Quality of Life, Regression Analysis, Surveys and Questionnaires, Time Factors, Transplantation Conditioning methods, Transplantation Conditioning statistics & numerical data, Transplantation, Autologous adverse effects, Young Adult, Cancer Survivors psychology, Health Knowledge, Attitudes, Practice, Hematopoietic Stem Cell Transplantation adverse effects, Lymphoma psychology
- Abstract
Purpose: Lymphoma survivors after high dose therapy with autologous stem cell therapy (HD-ASCT) are at high risk for late adverse effects (AEs). Information patients receive and collect throughout their cancer trajectory about diagnosis, treatment schedule and risks of AEs may influence attitudes and health-related behavior in the years after treatment. The purpose of this study was to explore level of knowledge in lymphoma survivors after HD-ASCT at a median of 12 years after primary diagnosis. Material and methods: From a national study on the effects of HD-ASCT for lymphomas, 269 survivors met for an outpatient examination, including a structured interview addressing knowledge about diagnosis and treatment. Survivors were also asked whether they knew and/or had experienced certain common late AEs. Numbers of recognized and experienced late AEs were presented as sum scores. Factors associated with the level of knowledge of late AEs were analyzed by linear regression analysis. Results: Eighty-one percent of the survivors knew their diagnosis, 99% knew the components of HD-ASCT and 97% correctly recalled having had radiotherapy. Ninety percent reported awareness of late AEs, but the level of knowledge and personal experience with specified AEs varied. Thirty-five percent of survivors stated to have received follow-up for late AEs. In multivariable analysis younger age at diagnosis, having received mediastinal radiotherapy, higher mental health related quality of life, a higher number of self-experienced late AEs and having received follow-up care for late AEs were significantly associated with a higher level of knowledge of AEs. Conclusion: The majority of lymphoma survivors treated with HD-ASCT correctly recalled diagnosis and treatment, while knowledge of late AEs varied. Our findings point to information deficits in survivors at older age and with lower mental health related quality of life. They indicate benefit of follow-up to enhance education on late AEs in lymphoma survivors.
- Published
- 2019
- Full Text
- View/download PDF
24. Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes.
- Author
-
Bersvendsen HS, Haugnes HS, Fagerli UM, Fluge Ø, Holte H, Smeland KB, Wilsgaard T, and Kiserud CE
- Subjects
- Adolescent, Adult, Aged, Cancer Survivors, Case-Control Studies, Child, Comorbidity, Cross-Sectional Studies, Fatigue etiology, Female, Humans, Lymphoma epidemiology, Lymphoma psychology, Middle Aged, Norway, Overweight epidemiology, Patient Reported Outcome Measures, Socioeconomic Factors, Hematopoietic Stem Cell Transplantation adverse effects, Life Style, Lymphoma therapy
- Abstract
Introduction: High-dose therapy with autologous stem cell transplantation (HD-ASCT) is associated with an increased risk of late effects. Our aim was to assess lifestyle behavior and factors associated with unhealthy lifestyle among HD-ASCT-treated lymphoma survivors (HD-ASCT-LS). Materials and methods: We conducted a national cross-sectional study of HD-ASCT-LS treated during 1987-2008. Among 399 eligible participants, 312 (78%) completed patient-reported outcome measures (PROMs) on lifestyle behavior (physical activity, overweight, smoking and alcohol consumption), chronic fatigue (CF) and somatic and mental illness. We assessed lifestyle according to WHO recommendations. Multivariable logistic regression models were used to study associations between variables. A comparison to the general population was performed. Results: Mean age at survey was 54.6 years, 60% were men, 55% sedentary, 55% overweight, 18% smokers and 5% had unhealthy alcohol consumption. Being sedentary was positively associated with older age, low household income, CF and higher somatic burden (≥4 self-reported somatic conditions). Overweight was positively associated with male gender and negatively associated with increased number of chemotherapy regimens prior to HD-ASCT. Current smoking was positively associated with living alone and CF, and negatively associated with older age. Male gender, CF and higher somatic burden increased the risk of an unhealthier lifestyle whereas the increased number of chemotherapy regimens prior to HD-ASCT decreased the risk. HD-ASCT-LS were significantly less sedentary, less overweight, and had a lower likelihood of smoking than the controls. Discussion: Assessed by PROMs, unhealthy habits were frequent among HD-ASCT-LS and associated with comorbidity. Nevertheless, compared with controls significantly more HD-ASCT-LS met lifestyle recommendations. These results indicate that the HD-ASCT-LS may consist of two groups, the adhering group with less comorbidity and the non-adhering group with more comorbidity. Our findings illustrate the necessity of recommendations and support for improving health-related behavior in cancer survivorship plans in order to empower survivors in their life beyond cancer.
- Published
- 2019
- Full Text
- View/download PDF
25. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity.
- Author
-
Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, and Kiserud CE
- Subjects
- Female, Hematopoietic Stem Cell Transplantation methods, Humans, Male, Prevalence, Transplantation, Autologous methods, Cardiorespiratory Fitness psychology, Fatigue Syndrome, Chronic etiology, Hematopoietic Stem Cell Transplantation adverse effects, Interleukin-6 adverse effects, Neuroticism physiology, Obesity etiology, Transplantation, Autologous adverse effects
- Published
- 2019
- Full Text
- View/download PDF
26. Runaway Train: A Leaky Radiosensitive SCID with Skin Lesions and Multiple Lymphomas.
- Author
-
Fevang B, Fagerli UM, Sorte H, Aarset H, Hov H, Langmyr M, Keil TM, Bjørge E, Aukrust P, Stray-Pedersen A, and Gedde-Dahl T
- Abstract
The nuclease Artemis is essential for the development of T-cell and B-cell receptors and repair of DNA double-strand breaks, and a loss of expression or function will lead to a radiosensitive severe combined immunodeficiency with no functional T-cells or B-cells (T-B-SCID). Hypomorphic mutations in the Artemis gene can lead to a functional, but reduced, T-cell and B-cell repertoire with a more indolent clinical course called "leaky" SCID. Here, we present the case of a young man who had increasingly aggressive lymphoproliferative skin lesions from 2 years of age which developed into multiple EBV+ B-cell lymphomas, where a hypomorphic mutation in the Artemis gene was found in a diagnostic race against time using whole exome sequencing. The patient was given a haploidentical stem cell transplant while in remission for his lymphomas and although the initial course was successful, he succumbed to a serious Pneumocystis jirovecii pneumonia 5 months after the transplant. The case underscores the importance of next-generation sequencing in the diagnosis of patients with suspected severe immunodeficiency.
- Published
- 2018
- Full Text
- View/download PDF
27. Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.
- Author
-
Hjort MA, Hov H, Abdollahi P, Vandsemb EN, Fagerli UM, Lund B, Slørdahl TS, Børset M, and Rø TB
- Abstract
Background: Phosphatase of regenerating liver-3 (PRL-3) is implicated in oncogenesis of hematological and solid cancers. PRL-3 expression increases metastatic potential, invasiveness and is associated with poor prognosis. With this study, we aimed to show a possible oncogenic role of PRL-3 in classical Hodgkin lymphoma (cHL)., Methods: PRL-3 expression was measured in 25 cHL patients by immunohistochemistry and gene expression was analyzed from microdissected malignant cells. We knocked down PRL-3 in the cHL cell lines L1236 and HDLM2 and used small molecular inhibitors against PRL-3 to investigate proliferation, migration and cytokine production., Results: PRL-3 protein was expressed in 16% of patient samples. In three different gene expression datasets, PRL-3 was significantly overexpressed compared to normal controls. PRL-3 knockdown reduced proliferation, viability and Mcl-1 expression in L1236, but not in HDLM2 cells. Thienopyridone, a small molecule inhibitor of PRL-3, reduced proliferation of both L1236 and HDLM2. PRL-3 affected IL-13 secretion and enhanced STAT6 signaling. IL-13 stimulation partially rescued proliferation in L1236 cells after knockdown of PRL-3. PRL-3 knockdown reduced migration in both L1236 and HDLM2 cells., Conclusion: PRL-3 was overexpressed in a subset of cHL patients. Inhibition of PRL-3 increased IL-13 cytokine production and reduced migration, proliferation and viability. The effects could be mediated through regulation of the anti-apoptotic molecule Mcl-1 and a feedback loop of IL-13 mediated activation of STAT6. This point to a role for PRL-3 in the pathogenesis of Hodgkin lymphoma, and PRL-3 could be a possible new drug target.
- Published
- 2018
- Full Text
- View/download PDF
28. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
- Author
-
Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, and Geisler CH
- Subjects
- Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm, Residual diagnosis, Neoplasm, Residual drug therapy, Recurrence, Scandinavian and Nordic Countries, Survival Analysis, Transplantation, Autologous, Treatment Outcome, Hematopoietic Stem Cell Transplantation methods, Lymphoma, Mantle-Cell therapy, Neoplasm, Residual prevention & control, Rituximab therapeutic use
- Abstract
The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P < .0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P < .0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies., (Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
29. Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.
- Author
-
Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, and Dahl AA
- Subjects
- Adult, Age Factors, Aged, Antineoplastic Agents therapeutic use, Comorbidity, Cross-Sectional Studies, Female, Follow-Up Studies, Humans, Lymphoma therapy, Male, Middle Aged, Norway epidemiology, Quality of Life, Retrospective Studies, Sex Factors, Stem Cell Transplantation, Surveys and Questionnaires, Survivors psychology, Transplantation, Autologous, Treatment Outcome, Unemployment statistics & numerical data, Employment statistics & numerical data, Lymphoma epidemiology, Survivors statistics & numerical data
- Abstract
Background This study examined employment patterns and associated factors in lymphoma survivors treated with high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT) from diagnosis to a follow-up survey at a mean of 10 years after HDT-ASCT. Patients and methods All lymphoma survivors aged ≥18 years at HDT-ASCT in Norway from 1987 to 2008, and alive at the end of 2011 were eligible for this cross-sectional study performed in 2012/2013. Participants completed a mailed questionnaire. Job status was dichotomized as either employed (paid work) or not-employed (disability and retirement pension, on economic support, home-makers, or students). Results The response rate was 78%, and the sample (N = 312) contained 60% men. Mean age at HDT-ASCT was 44.3 and at survey 54.0 years. At diagnosis 85% of survivors were employed, 77% before and 77% after HDT-ASCT, and 58% at follow-up. Forty seven percent of the survivors were employed at all time points. The not-employed group at survey was significantly older and included significantly more females than the employed group. No significant between-group differences were observed for lymphoma-related variables. Fatigue, mental distress and type D personality were significantly higher among those not-employed, while quality of life was significantly lower compared to the employed group. Older age at survey, being female, work ability and presence of type D personality remained significantly related to being not-employed at survey in the multivariable analysis. Conclusions Our findings show that not-employed long-term survivors after HDT-ASCT for lymphoma have more comorbidity, cognitive problems and higher levels of anxiety/depression than employed survivors. These factors should be checked and eventually treated in order to improve work ability.
- Published
- 2016
- Full Text
- View/download PDF
30. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.
- Author
-
Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, and Holte H
- Subjects
- Adolescent, Adult, Aged, Combined Modality Therapy methods, Combined Modality Therapy mortality, Female, Hematopoietic Stem Cell Transplantation mortality, Humans, Lymphoma, Non-Hodgkin complications, Lymphoma, Non-Hodgkin mortality, Male, Middle Aged, Norway epidemiology, Recurrence, Registries, Survival Analysis, Transplantation, Autologous, Young Adult, Hematopoietic Stem Cell Transplantation methods, Lymphoma, Non-Hodgkin therapy, Neoplasms, Second Primary etiology
- Abstract
This national population-based study aimed to investigate conditional survival and standardized mortality ratios (SMR) after high-dose therapy with autologous stem-cell transplantation (HDT-ASCT) for non-Hodgkin lymphoma (NHL), and to analyse cause of death, relapses and second malignancies. All patients ≥18 years treated with HDT-ASCT for NHL in Norway between 1987 and 2008 were included (n = 578). Information from the Cause of Death Registry and Cancer Registry of Norway were linked with clinical data. The 5-, 10- and 20-year overall survival was 61% (95% confidence interval [CI] 56-64%), 52% (95%CI 48-56%) and 45% (95%CI 40-50%), respectively. The 5-year survival conditional on having survived 2, 5 and 10 years after HDT-ASCT was 81%, 86% and 93%. SMRs were 12·3 (95%CI 11·0-13·9), 4·9 (95%CI 4·1-5·9), 2·4 (95%CI 1·8-3·2) and 1·0 (95%CI 0·6-1·8) for the entire cohort and for patients having survived 2, 5 and 10 years after HDT-ASCT respectively. Of the 281 deaths observed, 77% were relapse-related. Treatment-related mortality was 3·6%. The 10-year cumulative incidence of second malignancies was 7·9% and standardized incidence ratio was 2·0 (95%CI 1·5-2·6). NHL patients treated with HDT-ASCT were at increased risk of second cancer and premature death. The mortality was still elevated at 5 years, but after 10 years mortality equalled that of the general population., (© 2016 John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
31. PET/MR brain imaging: evaluation of clinical UTE-based attenuation correction.
- Author
-
Aasheim LB, Karlberg A, Goa PE, Håberg A, Sørhaug S, Fagerli UM, and Eikenes L
- Subjects
- Adult, Aged, Aged, 80 and over, Algorithms, Female, Humans, Male, Middle Aged, Organ Size, Skull anatomy & histology, Skull diagnostic imaging, Time Factors, Tomography, X-Ray Computed, Brain diagnostic imaging, Image Processing, Computer-Assisted methods, Magnetic Resonance Imaging methods, Positron-Emission Tomography
- Abstract
Unlabelled: One of the greatest challenges in PET/MR imaging is that of accurate MR-based attenuation correction (AC) of the acquired PET data, which must be solved if the PET/MR modality is to reach its full potential. The aim of this study was to investigate the performance of Siemens' most recent version (VB20P) of MR-based AC of head PET data, by comparing it to CT-based AC., Methods: (18)F-FDG PET data from seven lymphoma and twelve lung cancer patients examined with a Biograph mMR PET/MR system were reconstructed with both CT-based and MR-based AC, avoiding sources of error arising when comparing PET data from different systems. The resulting images were compared quantitatively by measuring changes in mean SUV in ten different brain regions in both hemispheres, as well as the brainstem. In addition, the attenuation maps (μ maps) were compared regarding volume and localization of cranial bone., Results: The UTE μ maps clearly overestimate the amount of bone in the neck, while slightly underestimating the amount of bone in the cranium, and the localization of bone in the cranial region also differ from the CT μ maps. In air/tissue interfaces in the sinuses and ears, the MRAC method struggles to correctly classify the different tissues. The misclassification of tissue is most likely caused by a combination of artefacts and the insufficiency of the UTE method to accurately separate bone. Quantitatively, this results in a combination of overestimation (0.5-3.6 %) and underestimation (2.7-5.2 %) of PET activity throughout the brain, depending on the proximity to the inaccurate regions., Conclusions: Our results indicate that the performance of the UTE method as implemented in VB20P is close to the theoretical maximum of such an MRAC method in the brain, while it does not perform satisfactorily in the neck or face/nasal area. Further improvement of the UTE MRAC or other available methods for more accurate segmentation of bone should be incorporated.
- Published
- 2015
- Full Text
- View/download PDF
32. Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.
- Author
-
Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, and Holte H
- Subjects
- Cohort Studies, Female, Hematopoietic Stem Cell Transplantation trends, Humans, Male, Neoplasms, Second Primary diagnosis, Norway epidemiology, Recurrence, Registries, Survival Rate trends, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation mortality, Hodgkin Disease mortality, Hodgkin Disease therapy, Neoplasms, Second Primary mortality
- Published
- 2015
- Full Text
- View/download PDF
33. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.
- Author
-
Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, and Fagerli UM
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Central Nervous System Neoplasms mortality, Central Nervous System Neoplasms pathology, Dacarbazine administration & dosage, Dacarbazine analogs & derivatives, Female, Follow-Up Studies, Humans, Lymphoma, Non-Hodgkin mortality, Lymphoma, Non-Hodgkin pathology, Maintenance Chemotherapy, Male, Middle Aged, Neoplasm Staging, Remission Induction, Survival Analysis, Temozolomide, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Central Nervous System Neoplasms drug therapy, Lymphoma, Non-Hodgkin drug therapy
- Abstract
The Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system lymphoma patients applying an age-adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance treatment. Patients aged 18-75 years were eligible. Thirty-nine patients aged 18-65 years and 27 patients aged 66-75 years were enrolled. The median age of the two age groups was 55 and 70 years, respectively. The overall response rate was 73.8% for the entire cohort: 69.9% in the younger and 80.8% in the elderly subgroup. With a median follow up of 22 months, the 2-year overall survival probability was 60.7% in patients aged 65 years or under and 55.6% in patients aged over 65 years (P=0.40). The estimated progression-free survival at two years was 33.1% (95%CI: 19.1%-47.9%) in patients aged under 65 years and 44.4% (95%CI: 25.6%-61.8%) in the elderly subgroup (P=0.74). Median duration of response was ten months in the younger subgroup, and not reached in the elderly patient subgroup (P=0.33). Four patients aged 64-75 years (6%) died from treatment-related complications. Survival in the two age groups was similar despite a de-escalation of induction treatment in patients aged over 65 years. Duration of response in elderly patients receiving maintenance temozolomide was longer than in the younger age subgroup. While toxicity during induction is still of concern, especially in the elderly patients, we conclude from these data that de-escalation of induction therapy in elderly primary central nervous system lymphoma patients followed by maintenance treatment seems to be a promising treatment strategy. (clinicaltrials.gov identifier:01458730)., (Copyright© Ferrata Storti Foundation.)
- Published
- 2015
- Full Text
- View/download PDF
34. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
- Author
-
Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N, and Geisler CH
- Subjects
- Adult, Aged, Carmustine administration & dosage, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Disease-Free Survival, Etoposide administration & dosage, Female, Humans, Kaplan-Meier Estimate, Male, Melphalan administration & dosage, Middle Aged, Multivariate Analysis, Neoplasm, Residual diagnosis, Prognosis, Radioimmunotherapy, Time Factors, Transplantation, Autologous, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Mantle-Cell therapy, Stem Cell Transplantation methods
- Abstract
The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years received rituximab (R)-maxi-CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) alternating with R-high-dose cytarabine (6 cycles total), followed by high-dose BEAM/C (bis-chloroethylnitrosourea, etoposide, cytarabine, and melphalan or cyclophosphamide) and autologous stem cell transplantation from 2005 to 2009. Zevalin (0.4 mCi/kg) was given to responders not in CR before transplant. Overall response rate pretransplant was 97%. The outcome did not differ from that of the historic control: the MCL2 trial with similar treatment except for Zevalin. Overall survival (OS), event-free survival (EFS), and progression-free survival (PFS) at 4 years were 78%, 62%, and 71%, respectively. For responding non-CR patients who received Zevalin, duration of response was shorter than for the CR group. Inferior PFS, EFS, and OS were predicted by positron emission tomography (PET) positivity pretransplant and detectable minimal residual disease (MRD) after transplant. In conclusion, positive PET and MRD were strong predictors of outcome. Intensification with Zevalin may be too late to improve the outcome of patients not in CR before transplant. This trial was registered at www.clinicaltrials.gov as #NCT00514475.
- Published
- 2014
- Full Text
- View/download PDF
35. High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.
- Author
-
Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, and Holte H
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy statistics & numerical data, Female, Humans, Lymphoma mortality, Male, Middle Aged, Norway epidemiology, Survival Rate, Transplantation, Autologous statistics & numerical data, Young Adult, Hematopoietic Stem Cell Transplantation statistics & numerical data, Lymphoma therapy
- Abstract
Background: High-dose therapy with autologous stem cell support (HDT) has been a treatment option for lymphomas in Norway for 25 years. The purpose of the article was to describe the use of the therapy for lymphomas for the country as a whole and by health region, and to reveal the overall survival rate., Method: All lymphoma patients ≥ 18 years who received HDT in Norway in the period 1987-2008 are included. Patients, diagnostics and treatment are identified for each hospital. Data for the population base have been retrieved from Statistics Norway., Results: Altogether 726 lymphoma patients received HDT in Norway in the period 1987-2008, with an annual average of 0.72 per 100,000 inhabitants. The annual number of treatments increased until 2004 and has since been stable. The average number of treatments per 100,000 inhabitants per year was 0.94 for Northern Norway Health Region, 0.80 for South-Eastern Norway Health Region, 0.58 for Central Norway Health Region and 0.55 for Western Norway Health Region. Early mortality (death within 100 days) was 6%. Ten-year overall survival was 55% (95% CI 51-59%), and Hodgkin's lymphoma had the best survival of the lymphoma groups (p = 0.01)., Interpretation: The annual number of HDT increased gradually until 2004. The use of the treatment varied according to the patients' place of residence at the time of diagnosis, and was most frequently used for patients belonging to Northern Norway Health Region. More than half of the lymphoma patients are alive ten years after the treatment.
- Published
- 2013
- Full Text
- View/download PDF
36. HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.
- Author
-
Rø TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, and Børset M
- Subjects
- Autocrine Communication, Cell Line, Tumor, Cell Movement drug effects, Chemokine CXCL12 physiology, Dose-Response Relationship, Drug, Drug Synergism, Enzyme Activation, Hepatocyte Growth Factor physiology, Humans, Insulin-Like Growth Factor I physiology, Neoplasm Proteins physiology, Proto-Oncogene Proteins c-met drug effects, RNA, Small Interfering pharmacology, Receptors, CXCR4 physiology, Recombinant Fusion Proteins physiology, Transfection, p21-Activated Kinases antagonists & inhibitors, p21-Activated Kinases genetics, Chemokine CXCL12 pharmacology, Hepatocyte Growth Factor pharmacology, Insulin-Like Growth Factor I pharmacology, Multiple Myeloma pathology, p21-Activated Kinases physiology
- Abstract
Stromal-derived factor (SDF)-1α, insulin-like growth factor (IGF)-1 and hepatocyte growth factor (HGF) are potent mediators of cell migration. We studied the effect of combinations of these cytokines on the migration of myeloma cells. When SDF-1α was combined with either HGF or IGF-1, we found a striking synergy in the cytokines' ability to guide cells across a transwell membrane. Between HGF and IGF-1 there was no cooperativity. However, the effects of HGF and IGF-1 were not redundant. HGF and SDF-1 caused concentration gradient-directed migration, as opposed to IGF-1, which apparently caused randomly directed cell movement. The SDF-1α-driven migration of JJN-3 cells, a myeloma cell line secreting large amounts of HGF, was reduced when JJN-3 cells were given an inhibitor of the HGF receptor, demonstrating a cooperative activity between autocrine HGF and exogenous SDF-1α. There was a clear positive correlation between the degree of cytokine-induced migration and phosphorylation of p21-activated kinase (PAK) both in primary myeloma cells and in cell lines including INA-6 and IH-1. Downregulation of PAK with small interfering RNA in INA-6 cells resulted in decreased cytokine-driven migration. This study shows synergy between SDF-1α and HGF/IGF-1 in inducing migration of myeloma cells, yet each cytokine has distinct properties in the way it regulates cell migration. These findings are likely to be of clinical relevance because multiple myeloma cells are located in an environment containing HGF and IGF-1 and are exposed to an SDF-1α gradient between the bone marrow and peripheral blood., (Copyright © 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
37. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
- Author
-
d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, and Toldbod HE
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chemotherapy, Adjuvant, Cyclophosphamide administration & dosage, Disease Progression, Disease-Free Survival, Doxorubicin administration & dosage, Etoposide administration & dosage, Europe, Female, Humans, Kaplan-Meier Estimate, Lymphoma, T-Cell, Peripheral mortality, Lymphoma, T-Cell, Peripheral pathology, Male, Middle Aged, Multivariate Analysis, Neoadjuvant Therapy, Prednisone administration & dosage, Proportional Hazards Models, Prospective Studies, Risk Assessment, Risk Factors, Time Factors, Transplantation, Autologous, Treatment Outcome, Vincristine administration & dosage, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, T-Cell, Peripheral therapy, Stem Cell Transplantation adverse effects, Stem Cell Transplantation mortality
- Abstract
Purpose: Systemic peripheral T-cell lymphomas (PTCLs) respond poorly to conventional therapy. To evaluate the efficacy of a dose-dense approach consolidated by up-front high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) in PTCL, the Nordic Lymphoma Group (NLG) conducted a large prospective phase II study in untreated systemic PTCL. This is the final report, with a 5-year median follow-up, of the NLG-T-01 study., Patients and Methods: Treatment-naive patients with PTCL age 18 to 67 years (median, 57 years) were included. Anaplastic lymphoma kinase (ALK) -positive anaplastic large-cell lymphoma (ALCL) was excluded. An induction regimen of six cycles of biweekly CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) was administered (in patients age > 60 years, etoposide was omitted). If in complete or partial remission, patients proceeded to consolidation with HDT/ASCT., Results: Of 166 enrolled patients, 160 had histopathologically confirmed PTCL. The majority presented with advanced-stage disease, B symptoms, and elevated serum lactate dehydrogenase. A total of 115 underwent HDT/ASCT, with 90 in complete remission at 3 months post-transplantation. Early failures occurred in 26%. Treatment-related mortality was 4%. At 60.5 months of median follow-up, 83 patients were alive. Consolidated 5-year overall and progression-free survival (PFS) were 51% (95% CI, 43% to 59%) and 44% (95% CI, 36% to 52%), respectively. Best results were obtained in ALK-negative ALCL., Conclusion: Dose-dense induction followed by HDT/ASCT was well tolerated and led to long-term PFS in 44% of treatment-naive patients with PTCL. This represents an encouraging outcome, particularly considering the high median age and adverse risk profile of the study population. Therefore, dose-dense induction and HDT/ASCT are a rational up-front strategy in transplantation-eligible patients with PTCL.
- Published
- 2012
- Full Text
- View/download PDF
38. Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.
- Author
-
Wader KF, Fagerli UM, Børset M, Lydersen S, Hov H, Sundan A, Bofin A, and Waage A
- Subjects
- Adult, Aged, Aged, 80 and over, Bone Marrow metabolism, Bone Marrow pathology, Bone Marrow Neoplasms classification, Bone Marrow Neoplasms metabolism, Cell Membrane metabolism, Cell Membrane pathology, Cytoplasm metabolism, Cytoplasm pathology, Disease Progression, Female, Humans, Male, Middle Aged, Multiple Myeloma classification, Multiple Myeloma metabolism, Phosphorylation, Plasma Cells metabolism, Bone Marrow Neoplasms diagnosis, Hepatocyte Growth Factor metabolism, Multiple Myeloma diagnosis, Plasma Cells pathology, Proto-Oncogene Proteins c-met metabolism
- Abstract
Aims: Interaction with the bone marrow microenvironment is important for homing and survival of myeloma cells. One cytokine involved in this process is hepatocyte growth factor (HGF). HGF, by binding to the receptor tyrosine kinase c-Met, mediates a broad range of tumour progression activities. Our aims were to investigate whether HGF and c-Met are present in bone marrow and extramedullary tumours from patients with monoclonal plasma cell disease, and whether c-Met is activated., Methods and Results: Expression of HGF, c-Met and phospho-c-Met was studied by immunohistochemistry in biopsies from 80 patients with monoclonal plasma cell disease. Cytoplasmic staining for HGF in plasma cells was demonstrated in 58 of 68 biopsies from multiple myeloma patients (85%), but also in biopsies from nine of 10 healthy individuals. Membranous staining for c-Met was found in 25 of 63 multiple myeloma patients (40%) and in none of 10 healthy individuals. Membranous staining for phospho-c-Met was found in biopsies from 15 of 21 c-Met-positive myeloma patients (71%)., Conclusions: Our data point to c-Met expression as one of the factors that distinguishes normal from malignant plasma cells, and indicate that the HGF/c-Met system is activated in multiple myeloma patients., (© 2012 Blackwell Publishing Limited.)
- Published
- 2012
- Full Text
- View/download PDF
39. Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.
- Author
-
Wader KF, Fagerli UM, Holt RU, Børset M, Sundan A, and Waage A
- Subjects
- Female, Humans, Male, Biomarkers, Tumor blood, Multiple Myeloma blood, Proto-Oncogene Proteins c-met blood
- Abstract
Objectives: The receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor (HGF), play key roles in tumour genesis and metastasis and contribute in multiple myeloma pathogenesis. Substantial data support that a soluble extracellular fragment of c-Met may function as a decoy receptor that downregulates the biological effects of HGF and c-Met. We examined serum levels of soluble c-Met in patients with myeloma and healthy individuals and investigated a possible relationship with clinical disease parameters and survival., Methods: The concentration of c-Met and HGF was measured by enzyme-linked immunosorbent assay in serum (n=49) and bone marrow plasma (n=16) from patients with multiple myeloma and in serum from healthy controls (n=26)., Results: The median serum concentration of soluble c-Met was 186 ng/mL (range 22-562) in patients with multiple myeloma and 189 ng/mL (range 124-397) in healthy individuals. There was a significant negative correlation between serum c-Met levels and disease stage, bone marrow plasma cell percentage and serum concentration of M-protein., Conclusion: We have for the first time examined the concentration of soluble c-Met in serum from patients with myeloma and found equal median levels in patients with myeloma as a group and healthy individuals. Still, serum levels of soluble c-Met correlated negatively with parameters of disease burden in patients with myeloma. We suggest that a possible role for the c-Met ectodomain as a negative regulator of HGF/c-Met activity should be examined in multiple myeloma., (© 2011 John Wiley & Sons A/S.)
- Published
- 2011
- Full Text
- View/download PDF
40. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
- Author
-
Fagerli UM, Ullrich K, Stühmer T, Holien T, Köchert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD Jr, Mathas S, Sundan A, Bargou RC, Dörken B, Børset M, and Janz M
- Subjects
- Bone Marrow Cells drug effects, Bone Marrow Cells pathology, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Cell Survival genetics, Cytokines metabolism, Down-Regulation genetics, Humans, Immediate-Early Proteins deficiency, Janus Kinases metabolism, Multiple Myeloma metabolism, Protein Serine-Threonine Kinases deficiency, RNA Interference, STAT3 Transcription Factor metabolism, Signal Transduction drug effects, Signal Transduction genetics, Cytokines pharmacology, Immediate-Early Proteins genetics, Multiple Myeloma genetics, Multiple Myeloma pathology, Protein Serine-Threonine Kinases genetics, Transcription, Genetic drug effects, Transcription, Genetic genetics
- Abstract
Multiple myeloma (MM) is a paradigm for a malignant disease that exploits external stimuli of the microenvironment for growth and survival. A thorough understanding of the complex interactions between malignant plasma cells and their surrounding requires a detailed analysis of the transcriptional response of myeloma cells to environmental signals. We determined the changes in gene expression induced by interleukin (IL)-6, tumor necrosis factor-α, IL-21 or co-culture with bone marrow stromal cells in myeloma cell lines. Among a limited set of genes that were consistently activated in response to growth factors, a prominent transcriptional target of cytokine-induced signaling in myeloma cells was the gene encoding the serine/threonine kinase serum/glucocorticoid-regulated kinase 1 (SGK1), which is a down-stream effector of PI3-kinase. We could demonstrate a rapid, strong and sustained induction of SGK1 in the cell lines INA-6, ANBL-6, IH-1, OH-2 and MM.1S as well as in primary myeloma cells. Pharmacologic inhibition of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway abolished STAT3 phosphorylation and SGK1 induction. In addition, small hairpin RNA (shRNA)-mediated knock-down of STAT3 reduced basal and induced SGK1 levels. Furthermore, downregulation of SGK1 by shRNAs resulted in decreased proliferation of myeloma cell lines and reduced cell numbers. On the molecular level, this was reflected by the induction of cell cycle inhibitory genes, for example, CDKNA1/p21, whereas positively acting factors such as CDK6 and RBL2/p130 were downregulated. Our results indicate that SGK1 is a highly cytokine-responsive gene in myeloma cells promoting their malignant growth.
- Published
- 2011
- Full Text
- View/download PDF
41. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.
- Author
-
Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, and Holte H
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Marrow Purging methods, Disease Progression, Drug Administration Schedule, Epidemiologic Methods, Female, Humans, Lymphoma, Follicular pathology, Lymphoma, Large B-Cell, Diffuse pathology, Male, Middle Aged, Recurrence, Salvage Therapy methods, Tissue and Organ Harvesting methods, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hematopoietic Stem Cell Transplantation methods, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
We present a prospective phase II study of patients with relapse after chemotherapy showing transformation of follicular lymphoma to diffuse large B-cell lymphoma, performed before rituximab was included in standard treatment. Patients in complete (CR) or partial remission (PR) after salvage chemotherapy were eligible for high-dose chemotherapy with autologous stem cell support (HDT). Forty-seven patients from five Norwegian centres were included, of whom 30 (63%) received HDT. Eighteen (60%) achieved CR, seven (23%) PR and five (10%) had progressive disease following HDT. Median follow-up for the surviving patients was 75 months; median progression-free (PFS) and overall survival (OS) were 26 and 47 months, respectively. Median OS for all patients was 43 months, compared to only 10 months for patients not eligible for HDT. Patients receiving CD34(+) enriched/B-cell depleted grafts had inferior PFS and a trend for inferior OS compared to patients receiving non-purged grafts (Log Rank 0·025 and 0·151, respectively). In conclusion, two thirds of patients with transformation of follicular lymphoma were eligible for HDT. The majority of patients achieved CR and a considerable number had prolonged OS. The use of in vitro purged grafts did not result in a survival benefit compared to that of non-purged grafts., (© 2011 Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
42. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.
- Author
-
Brenne AT, Fagerli UM, Shaughnessy JD Jr, Våtsveen TK, Rø TB, Hella H, Zhan F, Barlogie B, Sundan A, Børset M, and Waage A
- Subjects
- B-Cell Lymphoma 3 Protein, Case-Control Studies, Cell Cycle genetics, Cytokines pharmacology, Humans, Multiple Myeloma pathology, Prognosis, Proto-Oncogene Proteins metabolism, RNA, Messenger analysis, Survival Rate, Transcription Factors metabolism, Cell Proliferation, Gene Expression Regulation, Neoplastic drug effects, Multiple Myeloma genetics, Proto-Oncogene Proteins genetics, Transcription Factors genetics
- Abstract
Background: BCL3 is a putative oncogene encoding for a protein belonging to the inhibitory kappaB-family. We experienced that this putative oncogene was a common target gene for growth-promoting cytokines in myeloma cell lines., Methods: Gene expression of BCL3 was studied in 351 newly diagnosed myeloma patients, 12 patients with smouldering myeloma, 44 patients with monoclonal gammopathy of undetermined significance and 22 healthy individuals. Smaller material of samples was included for mRNA detection by RT-PCR, protein detection by Western blot and immunohistochemistry, and for cytogenetic studies. A total of eight different myeloma cell lines were studied., Results: Bcl-3 was induced in myeloma cell lines by interleukin (IL)-6, IL-21, IL-15, tumor necrosis factor-alpha and IGF-1, and its upregulation was associated with increased proliferation of the cells. In a population of 351 patients, expression levels of BCL3 above 75th percentile were associated with shorter 5-yr survival. When this patient population was divided into subgroups based on molecular classification, BCL3 was significantly increased in a poor risk subgroup characterized by overexpression of cell cycle and proliferation related genes. Intracellular localization of Bcl-3 was dependent on type of stimulus given to the cell., Conclusion: BCL3 is a common target gene for several growth-promoting cytokines in myeloma cells and high expression of BCL3 at the time of diagnosis is associated with poor prognosis of patients with multiple myeloma (MM). These data may indicate a potential oncogenic role for Bcl-3 in MM.
- Published
- 2009
- Full Text
- View/download PDF
43. c-Met signaling promotes IL-6-induced myeloma cell proliferation.
- Author
-
Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, and Sundan A
- Subjects
- Cell Line, Tumor, Cell Movement drug effects, Culture Media, Serum-Free, Drug Synergism, Flow Cytometry, Humans, In Situ Hybridization, Fluorescence, Proto-Oncogene Proteins c-met genetics, Recombinant Proteins pharmacology, Signal Transduction, Cell Division drug effects, Hepatocyte Growth Factor pharmacology, Interleukin-6 pharmacology, Multiple Myeloma pathology, Proto-Oncogene Proteins c-met metabolism
- Abstract
Objectives: Hepatocyte growth factor (HGF) is a constituent of the myeloma microenvironment and is elevated in sera from myeloma patients compared to healthy individuals. Increased levels of serum HGF predict a poor prognosis. It has previously been shown by us and others HGF can act as a growth factor to myeloma cells in vitro although these effects have been moderate. We therefore wanted to investigate if HGF could influence the effects of interleukin (IL)-6., Methods: Myeloma cell lines and primary samples were tested for the combined effects of IL-6 and HGF in inducing DNA synthesis and migration. Expression levels of c-Met protein were analysed by Western blotting and flow cytometry. Signaling pathways were examined by Western blotting using phosphospecific antibodies and a Ras-GTP pull down assay., Results: HGF potentiated IL-6-induced growth in human myeloma cell lines and in purified primary myeloma cells. There was also cooperation between HGF and IL-6 in induction of migration. There seemed to be two explanations for this synergy. IL-6-treatment increased the expression of c-Met making cells HGF responsive, and IL-6 was dependent on c-Met signaling in activating both Ras and p44/42 MAPK by a mechanism involving the tyrosine phosphatase Shp2., Conclusions: The results indicate that besides from being a myeloma growth factor alone, HGF can also potentiate the effects of IL-6 in myeloma proliferation and migration. Thus, c-Met signaling could be a target for therapy of multiple myeloma.
- Published
- 2009
- Full Text
- View/download PDF
44. Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.
- Author
-
Wader KF, Fagerli UM, Holt RU, Stordal B, Børset M, Sundan A, and Waage A
- Subjects
- Adult, Aged, Aged, 80 and over, Bone Marrow metabolism, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Norway, Retrospective Studies, Hepatocyte Growth Factor blood, Multiple Myeloma blood, Protein Precursors blood, Serine Endopeptidases blood
- Abstract
Objectives: Hepatocyte growth factor (HGF) is a potential key factor in multiple myeloma. Conversion of pro-HGF to its active form is a critical limiting step for its biological effects. We aimed to examine the levels of the most potent activator, the hepatocyte growth factor activator (HGFA), in serum and bone marrow plasma of patients with multiple myeloma., Methods: The activated form of HGFA was measured by an enzyme-linked immunosorbent assay in serum (n = 49) and bone marrow plasma (n = 16) from multiple myeloma patients, and in serum from healthy controls (n = 24)., Results: The median concentrations of activated HGFA in myeloma and control sera were 39.7 (range 6.2-450.0) and 17.6 ng/mL (range 4.8-280.6), respectively. The difference was statistically significant (P = 0.037). The median concentration of activated HGFA in bone marrow plasma was 6.1 ng/mL (range 3.5-30.0)., Conclusion: We here show for the first time that the activated form of HGFA is present at high levels in serum and bone marrow of myeloma patients, thus providing a necessary prerequisite for the activation of HGF.
- Published
- 2008
- Full Text
- View/download PDF
45. Hepatocyte growth factor promotes migration of human myeloma cells.
- Author
-
Holt RU, Fagerli UM, Baykov V, Rø TB, Hov H, Waage A, Sundan A, and Børset M
- Subjects
- Bone Marrow pathology, Cell Line, Tumor drug effects, Cell Line, Tumor pathology, Chemokine CXCL12 physiology, Cytokines pharmacology, Enzyme Inhibitors pharmacology, GTP-Binding Proteins analysis, Hepatocyte Growth Factor physiology, Humans, Indoles pharmacology, Integrin alpha4beta1 physiology, Intercellular Signaling Peptides and Proteins pharmacology, MAP Kinase Signaling System drug effects, MAP Kinase Signaling System physiology, Neoplasm Proteins antagonists & inhibitors, Phosphatidylinositol 3-Kinases physiology, Plasma Cells pathology, Protein Kinases analysis, Proto-Oncogene Proteins c-akt analysis, Proto-Oncogene Proteins c-met physiology, Recombinant Proteins pharmacology, Sulfones pharmacology, TOR Serine-Threonine Kinases, Tumor Cells, Cultured drug effects, Tumor Cells, Cultured pathology, Chemotaxis drug effects, Hepatocyte Growth Factor pharmacology, Multiple Myeloma pathology, Neoplasm Proteins physiology, Plasma Cells drug effects
- Abstract
Multiple myeloma is characterized by the accumulation and dissemination of malignant plasma cells in the bone marrow. Cell migration is thought to be important for these events. We studied migration in a Transwell two-chamber assay and tested the motogenic effect of various cytokines. In addition to insulin-like growth factor-1 and stromal cell-derived growth factor-1alpha, previously known as chemoattractants for myeloma cells, we identified hepatocyte growth factor as a potent attractant for myeloma cells. Hepatocyte growth factor-mediated migration was dependent on phosphatidylinositol-3-kinase, involved the MAPK/Erk signaling cascade and VLA-4 integrins, but did not involve Akt, mTOR or G proteins.
- Published
- 2008
- Full Text
- View/download PDF
46. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
- Author
-
Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, and Børset M
- Subjects
- Cell Cycle genetics, Cell Line, Tumor, Cytokines genetics, Cytokines metabolism, Female, Gene Silencing, Humans, Male, Multiple Myeloma pathology, Neoplasm Metastasis, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins genetics, Plasma Cells pathology, Protein Tyrosine Phosphatases antagonists & inhibitors, Protein Tyrosine Phosphatases genetics, RNA, Messenger biosynthesis, RNA, Messenger genetics, RNA, Neoplasm biosynthesis, RNA, Neoplasm genetics, Randomized Controlled Trials as Topic, Cell Movement genetics, Gene Expression Regulation, Neoplastic genetics, Multiple Myeloma metabolism, Neoplasm Proteins biosynthesis, Plasma Cells metabolism, Protein Tyrosine Phosphatases biosynthesis
- Abstract
Multiple myeloma (MM) is characterized by accumulation and dissemination of malignant plasma cells (PCs) in the bone marrow (BM). Gene expression profiling of 2 MM cell lines (OH-2 and IH-1) indicated that expression of PRL-3, a metastasis-associated tyrosine phosphatase, was induced by several mitogenic cytokines. Cytokine-driven PRL-3 expression could be shown in several myeloma cell lines at both the mRNA and protein levels. There was significantly higher expression of the PRL-3 gene in PCs from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), and myeloma than in PCs from healthy persons. Among 7 MM subgroups identified by unsupervised hierarchical cluster analysis, PRL-3 gene expression was significantly higher in the 3 groups denoted as "proliferation," "low bone disease," and "MMSET/FGFR3." PRL-3 protein was detected in 18 of 20 BM biopsies from patients with MM. Silencing of the PRL-3 gene by siRNA reduced cell migration in the MM cell line INA-6, but had no detectable effect on proliferation and cell-cycle phase distribution of the cells. In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells.
- Published
- 2008
- Full Text
- View/download PDF
47. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.
- Author
-
Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, and Sundan A
- Subjects
- Animals, Base Sequence, Bone Resorption genetics, Bone Resorption pathology, Cell Proliferation drug effects, Cells, Cultured, Core Binding Factor Alpha 1 Subunit genetics, Core Binding Factor Alpha 1 Subunit metabolism, DNA Primers genetics, Humans, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells drug effects, Mice, Osteoblasts metabolism, Osteoblasts pathology, Signal Transduction drug effects, Sp7 Transcription Factor, Transcription Factors genetics, Transcription Factors metabolism, Bone Morphogenetic Proteins pharmacology, Bone Resorption etiology, Hepatocyte Growth Factor pharmacology, Multiple Myeloma complications, Osteoblasts drug effects, Osteogenesis drug effects
- Abstract
The bone disease in multiple myeloma is caused by an uncoupling of bone formation from bone resorption. A key difference between patients with and patients without osteolytic lesion is that the latter have fewer and less active osteoblasts. Hepatocyte growth factor (HGF) is often produced by myeloma cells and is found at high concentrations in the bone marrow of patients with multiple myeloma. Here we show that HGF inhibited bone morphogenetic protein (BMP)-induced in vitro osteoblastogenesis. Thus, HGF inhibited BMP-induced expression of alkaline phosphatase in human mesenchymal stem cells (hMSCs) and the murine myoid cell line C2C12, as well as mineralization by hMSCs. Furthermore, the expression of the osteoblast-specific transcription factors Runx2 and Osterix was reduced by HGF treatment. HGF promoted proliferation of hMSCs, and the BMP-induced halt in proliferation was overridden by HGF, keeping the cells in a proliferative, undifferentiating state. BMP-induced nuclear translocation of receptor-activated Smads was inhibited by HGF, providing a possible explanation of how HGF inhibits BMP signaling. The in vitro data were supported by the observation of a negative correlation between HGF and a marker of osteoblast activity, bone-specific alkaline phosphatase (rho = -0.45, P = .008), in sera from 34 patients with myeloma. These observations suggest that HGF inhibits bone formation in multiple myeloma.
- Published
- 2007
- Full Text
- View/download PDF
48. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
- Author
-
Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, and Børset M
- Subjects
- Animals, Cell Adhesion drug effects, Cell Line, Cell Line, Tumor, Dose-Response Relationship, Drug, Hepatocyte Growth Factor metabolism, Humans, Immunoblotting, Interleukin-11 metabolism, Multiple Myeloma drug therapy, Multiple Myeloma metabolism, Multiple Myeloma pathology, Phosphorylation drug effects, Proto-Oncogene Proteins c-met metabolism, Signal Transduction drug effects, Transforming Growth Factor beta pharmacology, Tyrosine metabolism, Cell Movement drug effects, Cell Proliferation drug effects, Hepatocyte Growth Factor pharmacology, Indoles pharmacology, Proto-Oncogene Proteins c-met antagonists & inhibitors, Sulfones pharmacology
- Abstract
Purpose: We wanted to examine the role of the hepatocyte growth factor (HGF) receptor c-Met in multiple myeloma by applying a novel selective small molecule tyrosine kinase inhibitor, PHA-665752, directed against the receptor., Experimental Design: Four biological sequels of HGF related to multiple myeloma were studied: (1) proliferation of myeloma cells, (2) secretion of interleukin-11 from osteogenic cells, (3) migration of myeloma cells, and (4) adhesion of myeloma cells to fibronectin. We also examined effects of the c-Met inhibitor on intracellular signaling pathways in myeloma cells., Results: PHA-665752 effectively blocked the biological responses to HGF in all assays, with 50% inhibition at 5 to 15 nmol/L concentration and complete inhibition at around 100 nmol/L. PHA-665752 inhibited phosphorylation of several tyrosine residues in c-Met (Tyr(1003), Tyr(1230/1234/1235), and Tyr(1349)), blocked HGF-mediated activation of Akt and p44/42 mitogen-activated protein kinase, and prevented the adaptor molecule Gab1 from complexing with c-Met. In the HGF-producing myeloma cell line ANBL-6, PHA-665752 revealed an autocrine HGF-c-Met-mediated growth loop. The inhibitor also blocked proliferation of purified primary myeloma cells, suggesting that autocrine HGF-c-Met-driven growth loops are important for progression of multiple myeloma., Conclusions: Collectively, these findings support the role of c-Met and HGF in the proliferation, migration, and adhesion of myeloma cells and identify c-Met kinase as a therapeutic target for treatment of patients with multiple myeloma.
- Published
- 2004
- Full Text
- View/download PDF
49. [Injuries in handball players].
- Author
-
Fagerli UM, Lereim I, and Sahlin Y
- Subjects
- Age Factors, Female, Humans, Male, Seasons, Sex Factors, Athletic Injuries
- Abstract
The study involves 421 patients who had suffered injury while playing handball. It describes mechanism and trauma, the injuries and their consequences, and data on training and technical conditions. 2/3 of the injured were female and one half belonged to the younger age-classes. The incidence of injury was highest among senior players. Distortion was the most frequent type of injury, followed by contusions and fractures. Half of the injuries were to the upper limbs, but the most frequent single injury was injury to the ankle joint. Many fractures were seen in fingers, forearm, hand and ribs. Wounds occurred most frequently to the face. The most serious injuries were ruptures of the ligaments in the knee joint. Protective equipment, such as braces, was seldom used. A small minority of the players were given adequate first aid. Important measures to prevent injury include better basic training, better technical training conditions, good first aid, and some changes in the rules of competition.
- Published
- 1990
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.